HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ying Hou Selected Research

pseudoginsenoside F11 (PF 11)

10/2021Pseudoginsenoside-F11 ameliorates thromboembolic stroke injury in rats by reducing thromboinflammation.
10/2021Pseudoginsenoside-F11 promotes functional recovery after transient cerebral ischemia by regulating the microglia/macrophage polarization in rats.
8/2020Pseudoginsenoside-F11 ameliorates ischemic neuron injury by regulating the polarization of neutrophils and macrophages in vitro.
10/2019Pseudoginsenoside-F11 Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Neutrophil Infiltration and Accelerating Neutrophil Clearance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ying Hou Research Topics

Disease

21Neoplasms (Cancer)
10/2022 - 06/2006
6Inflammation (Inflammations)
02/2022 - 09/2017
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2018 - 01/2016
4Mitochondrial Diseases (Mitochondrial Disease)
06/2022 - 12/2017
4Necrosis
06/2022 - 01/2020
4Lung Neoplasms (Lung Cancer)
01/2021 - 01/2016
3Colonic Neoplasms (Colon Cancer)
07/2022 - 01/2020
3Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
10/2021 - 04/2012
3Dermatomyositis (Dermatopolymyositis)
05/2021 - 09/2017
3Tuberculosis (Tuberculoses)
01/2019 - 12/2011
3Infections
01/2019 - 07/2010
3Morphine Dependence
11/2010 - 12/2008
2Liver Diseases (Liver Disease)
07/2022 - 10/2021
2Carcinogenesis
01/2022 - 06/2006
2Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 01/2020
2Ischemic Stroke
10/2021 - 09/2020
2Transient Ischemic Attack
10/2021 - 08/2020
2Stroke (Strokes)
10/2021 - 07/2017
2Myositis (Idiopathic Inflammatory Myopathies)
05/2021 - 01/2019
2Frailty
01/2021 - 01/2018
2Wounds and Injuries (Trauma)
01/2021 - 01/2015
2Parkinson Disease (Parkinson's Disease)
01/2021 - 03/2013
2Insulin Resistance
12/2020 - 09/2020
2Hypertension (High Blood Pressure)
12/2020 - 09/2020
2Fibrosis (Cirrhosis)
09/2020 - 07/2016
2Glioma (Gliomas)
01/2020 - 01/2013
2Body Weight (Weight, Body)
10/2019 - 01/2010
2Hepatocellular Carcinoma (Hepatoma)
05/2018 - 01/2014
2Hypoxia (Hypoxemia)
02/2018 - 10/2007
2Hydronephrosis
12/2016 - 04/2006
2Ureteral Obstruction
07/2016 - 01/2015
2Wilms Tumor (Wilm's Tumor)
10/2007 - 06/2006
1Cardiotoxicity
06/2022
1Asthma (Bronchial Asthma)
02/2022
1Colitis-Associated Neoplasms
01/2022

Drug/Important Bio-Agent (IBA)

20Proteins (Proteins, Gene)FDA Link
07/2022 - 06/2006
7Pharmaceutical PreparationsIBA
10/2021 - 12/2008
6Therapeutic UsesIBA
10/2021 - 07/2010
4Protein Kinases (Protein Kinase)IBA
10/2022 - 12/2008
4CalciumIBA
06/2022 - 10/2019
4ocotillolIBA
10/2021 - 10/2019
4pseudoginsenoside F11 (PF 11)IBA
10/2021 - 10/2019
4Biomarkers (Surrogate Marker)IBA
10/2020 - 03/2015
3Neuroprotective AgentsIBA
10/2021 - 08/2020
3LipopolysaccharidesIBA
10/2021 - 07/2010
3SaponinsIBA
10/2021 - 10/2019
3Oxidoreductases (Dehydrogenase)IBA
05/2021 - 01/2020
2Reactive Oxygen Species (Oxygen Radicals)IBA
07/2022 - 01/2020
2IronIBA
06/2022 - 10/2021
2FlavonoidsIBA
06/2022 - 10/2021
2SolutionsIBA
02/2022 - 01/2021
2Dextran SulfateIBA
01/2022 - 10/2021
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2022 - 01/2021
2nannocystin AxIBA
11/2021 - 01/2021
2AntibodiesIBA
05/2021 - 01/2019
2geniposideIBA
01/2021 - 12/2020
2Messenger RNA (mRNA)IBA
01/2021 - 06/2006
2Interleukin-10 (Interleukin 10)IBA
01/2021 - 11/2019
2Estrogen ReceptorsIBA
12/2020 - 09/2020
2quinone (benzoquinone)IBA
10/2020 - 01/2020
2NAD (NADH)IBA
10/2020 - 01/2020
2Heat-Shock Proteins (Heat-Shock Protein)IBA
09/2020 - 06/2006
2Phosphotransferases (Kinase)IBA
01/2020 - 10/2019
2JNK Mitogen-Activated Protein KinasesIBA
01/2020 - 10/2019
22-methoxy-6-acetyl-7-methyljugloneIBA
01/2020 - 10/2019
2CytokinesIBA
11/2019 - 07/2016
2InterferonsIBA
01/2019 - 12/2011
2Tuberculin (PPD)IBA
01/2019 - 12/2011
2Epidermal Growth Factor (EGF)IBA
01/2013 - 04/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2012 - 10/2007
2Morphine (MS Contin)FDA LinkGeneric
01/2012 - 01/2010
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
06/2006 - 04/2006
1NF-kappa B (NF-kB)IBA
10/2022
1Annexin A5IBA
07/2022
1psoralidinIBA
07/2022
1Caspase 3 (Caspase-3)IBA
07/2022
15,5',6,6'- tetrachloro- 1,1',3,3'- tetraethylbenzimidazolocarbocyanineIBA
06/2022
1ChloridesIBA
06/2022
1Matrix Metalloproteinases (MMPs)IBA
06/2022
1Hemin (Panhematin)FDA Link
06/2022
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
06/2022
1tetramethylrhodamine methyl esterIBA
06/2022
1ferric ammonium citrateFDA Link
06/2022
1Small Interfering RNA (siRNA)IBA
06/2022
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2022
1Connexin 43 (Connexin43)IBA
02/2022
1Claudin-5IBA
02/2022
1Interleukin-4 (Interleukin 4)IBA
02/2022
1OvalbuminIBA
02/2022
1Aluminum Hydroxide (Algeldrate)FDA Link
02/2022
1Immunoglobulin E (IgE)IBA
02/2022
1cadherin 5IBA
02/2022
1Phenolsulfonphthalein (Phenol Red)IBA
02/2022
1ConnexinsIBA
02/2022
1neferineIBA
01/2022

Therapy/Procedure

5Radiotherapy
01/2018 - 01/2016
2Immunotherapy
10/2022 - 11/2012
2Intraperitoneal Injections
02/2022 - 10/2019
2Therapeutics
01/2017 - 12/2016
2Drug Therapy (Chemotherapy)
01/2017 - 07/2010